Shanxi Zhendong PharmaceuticalLtd Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Lianmin Yang

Chief executive officer

CN¥678.5k

Total compensation

CEO salary percentage	n/a
CEO tenure	2.8yrs
CEO ownership	n/a
Management average tenure	2.8yrs
Board average tenure	2.4yrs

Recent management updates

Recent updates

CEO

Lianmin Yang (61 yo)

2.8yrs

Tenure

CN¥678,500

Compensation

Mr. Lianmin Yang is President of Shanxi Zhendong Pharmaceutical Co.,Ltd from December 02, 2021 and had been its Deputy General Manager since April 24, 2021 and serves as its Director. He has M.B.A. from Ch...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Lianmin Yang	President & Director	2.8yrs	CN¥678.50k	no data
Changlu Liu	Head of Accounting & CFO	5.9yrs	CN¥375.40k	no data
Zheyu Wang	VP & Secretary of the Board of Director	1.3yrs	CN¥521.50k	no data
Xufeng Wang	Executive GM & Director	no data	no data	no data

2.8yrs

Average Tenure

40yo

Average Age

Experienced Management: 300158's management team is considered experienced (2.8 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Lianmin Yang	President & Director	no data	CN¥678.50k	no data
Xufeng Wang	Executive GM & Director	1.4yrs	no data	no data
Zhixiang Jin	Supervisor	12.8yrs	no data	0.077% CN¥ 2.8m
Ren Hu Li	Chairman of the Supervisory Board	15.8yrs	no data	0.084% CN¥ 3.1m
Zhimin Wang	Director	15.8yrs	CN¥83.30k	no data
Jing Li	Director	6.2yrs	CN¥694.70k	no data
Kun Li	Director	2.4yrs	CN¥688.30k	no data
Lina Jin	Independent Director	less than a year	no data	no data
Wanliang Lv	Independent Director	less than a year	no data	no data
Xuemei Qin	Independent Director	9.3yrs	no data	no data
Jiawen Ai	Non-Independent Director	no data	no data	no data
Zhenhong Lei	Supervisor	no data	no data	no data

2.4yrs

Average Tenure

60yo

Average Age

Experienced Board: 300158's board of directors are not considered experienced ( 2.4 years average tenure), which suggests a new board.

Shanxi Zhendong PharmaceuticalLtd Management

Management criteria checks 2/4

Key information

Recent management updates

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board and Non-Employee Supervisor Elections

High number of new directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Less than half of directors are independent

Less than half of directors are independent

No independent directors

Recent updates

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Board and Non-Employee Supervisor Elections

Second quarter 2024 earnings released: EPS: CN¥0.007 (vs CN¥0.014 in 2Q 2023)

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report First Half, 2024 Results on Aug 27, 2024

High number of new directors

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, May 17, 2024

Full year 2023 earnings released: CN¥0.043 loss per share (vs CN¥0.05 loss in FY 2022)

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Q1, 2024 Results on Apr 23, 2024

Now 20% undervalued

Shanxi Zhendong Pharmaceutical Co.,Ltd to Report Fiscal Year 2023 Results on Apr 23, 2024

New minor risk - Share price stability

Now 21% undervalued after recent price drop

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: CN¥0.014 (vs CN¥0.015 in 2Q 2022)

Full year 2022 earnings released: CN¥0.05 loss per share (vs CN¥2.55 profit in FY 2021)

Investor sentiment improves as stock rises 19%

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥0 (vs CN¥0.10 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥0.015 (vs CN¥0.12 in 2Q 2021)

Investor sentiment deteriorated over the past week

Upcoming dividend of CN¥2.70 per share

Shanxi Zhendong Pharmaceutical Co.,Ltd. Announces Final Dividend on A Shares for the Year 2021, Payable on 09 May 2022

First quarter 2022 earnings released: EPS: CN¥0.009 (vs CN¥0.095 in 1Q 2021)

No independent directors

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves 2021 Profit Distribution Plan

Investor sentiment deteriorated over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd, Annual General Meeting, Apr 22, 2022

Shanxi Zhendong Pharmaceutical Co.,Ltd Proposes Final Cash Dividend for 2021

Full year 2021 earnings released: EPS: CN¥2.56 (vs CN¥0.26 in FY 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment improved over the past week

Third quarter 2021 earnings released: EPS CN¥0.10 (vs CN¥0.087 in 3Q 2020)

FountainVest Capital Partners Fund IV, L.P., a fund managed by Fountain Vest Capital Partners GP4 Ltd. entered into an agreement to acquire Beijing Zhendong Langdi Pharmaceutical Co., Ltd. from Shanxi Zhendong Pharmaceutical Co.,Ltd (SZSE:300158) for CNY 5.8 billion.

Second quarter 2021 earnings released: EPS CN¥0.12 (vs CN¥0.055 in 2Q 2020)

Investor sentiment improved over the past week

Investor sentiment improved over the past week

Shanxi Zhendong Pharmaceutical Co.,Ltd Approves Final Profit for 2020

Shanxi Zhendong Pharmaceutical Co.,Ltd Announces Final Profit Distribution Proposal for 2020

Full year 2020 earnings released: EPS CN¥0.26 (vs CN¥0.14 in FY 2019)

Investor sentiment deteriorated over the past week

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Average Age

Board Members

Average Tenure

Average Age